Relugolix Completed Phase 3 Trials for Uterine Fibroids (Leiomyomas) Treatment

CompletedTreatment3 IdentifierTitleDrugs
NCT02655237A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
NCT02655224A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids